Very recently, in a study by Cruz et al. [44], the authors revealed that coincident high-mean mRNA expression of JAM-A, HER2, and FOXA1 is associated with poorer survival outcomes in HER2-positive (but not HER2-negative) patients with either breast or gastric tumors. This evidence concerns the gene ERBB2 and gastric neoplasm.